Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Plus Lenalidomide in MDS With Isolated del5q
NCT02928419Phase 2Terminated
- Sponsor
- Qol-one
- Start
- May 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in myelodysplastic syndrome (MDS), sponsored by Qol-one. Primary endpoint: Response (patients number with composite endpoint experience) at 24 weeks. Started May 2015; status: terminated.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02928419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928419.